Bionano Genomics Financial Statements (BNGO)
|
|
|
|
Report date
|
|
|
10.03.2020 |
23.03.2021 |
01.03.2022 |
09.03.2023 |
05.03.2024 |
|
14.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
10.1 |
8.50 |
18.0 |
27.8 |
36.1 |
|
33.3 |
|
Operating Income, bln rub |
|
|
-25.9 |
-38.6 |
-77.1 |
-131.7 |
-215.2 |
|
-108.1 |
|
EBITDA, bln rub |
? |
|
-26.4 |
-37.1 |
-73.9 |
-120.3 |
-213.6 |
|
-120.3 |
|
Net profit, bln rub |
? |
|
-29.8 |
-41.1 |
-72.4 |
-132.6 |
-232.5 |
|
-135.8 |
|
|
OCF, bln rub |
? |
|
-29.5 |
-38.3 |
-71.9 |
-124.8 |
-125.2 |
|
-96.7 |
|
CAPEX, bln rub |
? |
|
0.061 |
0.000 |
1.46 |
3.30 |
1.69 |
|
0.848 |
|
FCF, bln rub |
? |
|
-29.6 |
-38.3 |
-73.4 |
-128.1 |
-126.9 |
|
-97.6 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
29.2 |
41.3 |
81.0 |
137.6 |
149.0 |
|
93.2 |
|
Cost of production, bln rub |
|
|
6.77 |
5.73 |
14.1 |
21.9 |
26.6 |
|
33.9 |
|
R&D, bln rub |
|
|
9.08 |
10.3 |
22.5 |
49.0 |
54.0 |
|
33.0 |
|
Interest expenses, bln rub |
|
|
2.29 |
2.52 |
0.927 |
0.298 |
5.12 |
|
5.09 |
|
|
Assets, bln rub |
|
|
30.2 |
60.4 |
377.1 |
307.5 |
214.4 |
|
87.4 |
|
Net Assets, bln rub |
? |
|
3.61 |
35.1 |
337.1 |
249.4 |
96.2 |
|
48.9 |
|
Debt, bln rub |
|
|
20.0 |
16.3 |
10.7 |
11.7 |
79.4 |
|
22.5 |
|
Cash, bln rub |
|
|
17.3 |
38.4 |
250.6 |
113.2 |
101.9 |
|
8.79 |
|
Net debt, bln rub |
|
|
2.71 |
-22.1 |
-239.9 |
-101.5 |
-22.5 |
|
13.7 |
|
|
Ordinary share price, rub |
|
|
12.4 |
30.8 |
29.9 |
14.6 |
1.89 |
|
1.47 |
|
Number of ordinary shares, mln |
|
|
1.50 |
10.4 |
27.7 |
28.9 |
34.2 |
|
85.9 |
|
|
Market cap, bln rub |
|
|
19 |
321 |
828 |
422 |
65 |
|
126 |
|
EV, bln rub |
? |
|
21 |
299 |
588 |
321 |
42 |
|
140 |
|
Book value, bln rub |
|
|
4 |
26 |
254 |
131 |
62 |
|
38 |
|
|
EPS, rub |
? |
|
-19.9 |
-3.95 |
-2.62 |
-4.58 |
-6.81 |
|
-1.58 |
|
FCF/share, rub |
|
|
-19.8 |
-3.68 |
-2.65 |
-4.43 |
-3.72 |
|
-1.14 |
|
BV/share, rub |
|
|
2.41 |
2.54 |
9.18 |
4.53 |
1.82 |
|
0.44 |
|
|
EBITDA margin, % |
? |
|
-260.4% |
-436.1% |
-410.7% |
-432.8% |
-591.4% |
|
-360.9% |
|
Net margin, % |
? |
|
-294.5% |
-483.8% |
-402.8% |
-476.9% |
-643.7% |
|
-407.3% |
|
FCF yield, % |
? |
|
-159.3% |
-11.9% |
-8.87% |
-30.3% |
-196.6% |
|
-77.3% |
|
ROE, % |
? |
|
-825.6% |
-117.3% |
-21.5% |
-53.2% |
-241.8% |
|
-277.9% |
|
ROA, % |
? |
|
-98.8% |
-68.0% |
-19.2% |
-43.1% |
-108.4% |
|
-155.4% |
|
|
P/E |
? |
|
-0.62 |
-7.81 |
-11.4 |
-3.18 |
-0.28 |
|
-0.93 |
|
P/FCF |
|
|
-0.63 |
-8.38 |
-11.3 |
-3.30 |
-0.51 |
|
-1.29 |
|
P/S |
? |
|
1.83 |
37.8 |
46.0 |
15.2 |
1.79 |
|
3.79 |
|
P/BV |
? |
|
5.14 |
12.1 |
3.26 |
3.22 |
1.04 |
|
3.34 |
|
EV/EBITDA |
? |
|
-0.81 |
-8.06 |
-7.96 |
-2.67 |
-0.20 |
|
-1.16 |
|
Debt/EBITDA |
|
|
-0.10 |
0.60 |
3.25 |
0.84 |
0.11 |
|
-0.11 |
|
|
R&D/CAPEX, % |
|
|
14 873% |
|
1 540% |
1 485% |
3 195% |
|
3 895% |
|
|
CAPEX/Revenue, % |
|
|
0.60% |
0.00% |
8.12% |
11.9% |
4.68% |
|
2.54% |
|
| Bionano Genomics shareholders |
